• Highly experienced biotech executive, with over a quarter of a century of CNS drug discovery experience

• Dr. Beher takes over the role of Chief Executive Officer from co-founder Dr. Thomas Schulze

• FundaMental Pharma recently raised additional seed funding from new investor, the Novartis Venture Fund, bringing its total seed financing to €12.7 million

Heidelberg, Germany, 11 April 2024 – FundaMental Pharma GmbH (‘FundaMental’ or ‘The Company’), a neuroscience company developing first-in-class small molecule inhibitors for thetreatment of a range of neurodegenerative diseases, is pleased to announce the appointment of Dr.Dirk Beher as Chief Executive Officer and Executive Board member. Dr. Beher assumes this role from Dr. Thomas Schulze, who co-founded FundaMental and has been at the helm since its inception. Dr. Schulze will transition to the Board of Directors as part of a carefully planned succession strategy.